# Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer

> **NCT07674732** · PHASE2 · RECRUITING · sponsor: **Dechang Diao** · enrollment: 76 (estimated)

## Conditions studied

- Short-course Radiotherapy Plus Chemotherapy
- Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab

## Interventions

- **OTHER:** Short-course Radiotherapy plus Chemotherapy
- **OTHER:** Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab

## Key facts

- **NCT ID:** NCT07674732
- **Lead sponsor:** Dechang Diao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-24
- **Primary completion:** 2029-06-24
- **Final completion:** 2029-06-24
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674732, "Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07674732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*